Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults

References

• Battaglino R, Vokes M, Schulze-Spate U, Sharma A, Graves D, Kohler T, et al. 2007. Fluoxetine treatment increases trabecular bone formation in mice. J Cell Biochem 100:1387–1394.
   PubMed Web of Science ®Google Scholar
• Beevers CG, Marti CN, Lee HJ, Stote DL, Ferrell RE, Hariri AR, Telch MJ. 2011. Associations between serotonin transporter gene promoter region (5-HTTLPR) polymorphism and gaze bias for emotional information. J Abnorm Psychol 120:187–197.
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med 356: 1809–1822.
   PubMed Web of Science ®Google Scholar
• Bliziotes M. 2010. Update in serotonin and bone. J Clin Endocrinol Metab 95:4124–4132.
   PubMed Web of Science ®Google Scholar
• Bliziotes M, Eshleman A, Burt-Pichat B, Zhang XW, Hashimoto J, Wiren K, Chenu C. 2006. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 39:1313–1321.
   PubMed Web of Science ®Google Scholar
• Bliziotes MM, Eshleman AJ, Zhang XW, Wiren KM. 2001. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29:477–486.
   PubMed Web of Science ®Google Scholar
• Calarge CA, Ellingrod VL, Zimmerman B, Bliziotes MM, Schlechte JA. 2011. Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin psychiatry 72:1685–1690.
   PubMed Web of Science ®Google Scholar
• Civitelli R, Aramamento-Villareal R, Napoli N. 2009. Bone turnover markers: Understanding their value in clinical trials and clinical practice. Osteoporo Int 20:843–851.
   PubMed Web of Science ®Google Scholar
• Collet C, Schiltz C, Geoffroy V, Maroteaux L, Launay JM, de Vernejoul MC. 2008. The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J 22:418–427.
   PubMed Web of Science ®Google Scholar
• Conner TS, Jensen KP, Tennen H, Furneaux HM, Kranzler HR, Covault J. 2010. Functional polymorphisms in the serotonin 1B receptor gene (HTR1B) predict self-reported anger and hostility amoong young men. Am J Med Genet B: Neuropsychiatr Genet 153:B67–78.
   Google Scholar
• Crandall CJ, Miller-Martinez D, Greendale GA, Binkley N, Seeman TE, Karlamangla AS. 2012. Socioeconomic status, race, and bone turnover in the Midlife in the US Study. Osteoporo Int 23:1503–1512.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. 2009. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765.
   PubMed Web of Science ®Google Scholar
• Dempster DW. 2011. Osteoporosis and the burden of osteoporois-related fractures. Am J Managed Care 17:S164–S169.
   PubMedGoogle Scholar
• Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, Ensrud KE. 2007. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 167:1240–1245.
   PubMed Web of Science ®Google Scholar
• Dombrovski AY, Mulsant BH, Ferrell RE, Lotrich FE, Rosen JI, Wallace M, et al. 2010. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol 25:37–45.
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M. 1996. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version: Administration Booklet. Washington, DC: NIH.
   Google Scholar
• Frodl T, Zill P, Baghai T, Schule C, Rupprecht R, Zetzsche T, et al. 2008. Reduced hippocampal volumes associated with the long variant of the tri- and diallelic serotonin transporter polymorphism in major depression. Am J Med Genet B Neuropsychiatr Genet 147:B1003–1007.
   Google Scholar
• Gelernter J, Kranzler HR, Cubells JF. 1997. Serotonin transporter protein (SLC6A4) allele haplotype frequencies and linkage disequilibrium in African- and European-American and Japanese populations in alcohol-dependent subjects. Hum Genet 101:243–246.
   PubMed Web of Science ®Google Scholar
• Gustafsson BI, Thommesen L, Stunes AK, Tommeras K, Westbroek I, Waldum HL, et al. 2006. Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98: 139–151.
   PubMed Web of Science ®Google Scholar
• Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, et al. 2007. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Inter Med 167:1246–1251.
   PubMed Web of Science ®Google Scholar
• Haney EM, Warden SJ, Bliziotes MM. 2010. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?. Bone 46:13–17.
   PubMed Web of Science ®Google Scholar
• Hodge JM, Wang Y, Berk M, Collier FM, Fernandes TJ, Constable MJ, et al. 2012. Selective seritonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry pii: S0006-3223(12)00982-1.
   PubMed Web of Science ®Google Scholar
• Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. 2006. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78:815–826.
   PubMed Web of Science ®Google Scholar
• Joel I,Begley AE,Mulsant BH,Lenze EJ,Dew MA, Blumberger D, et al. 2014. Dynamic prediction of treat ment response in late-life depression. Am J Geriatr Psychiatry 22:167–176.
   PubMed Web of Science ®Google Scholar
• Karsenty G, Oury F. 2010. The central reguation of bone mass, the first link betwen bone remodeling and energy metabolism. J Clin Endocrinol Metab 95:4795–4801.
   PubMed Web of Science ®Google Scholar
• Karsenty G, Yadav VK. 2011. Regulation of bone mass by serotonin: molecular biology and therapeutic implications. Annu Rev Med 62:323–331.
   PubMed Web of Science ®Google Scholar
• Kenna GA, Rodger-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, et al. 2012. Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. Pharmacogen Personal Med 5:19–35.
   PubMedGoogle Scholar
• Lenze EJ,Dixon D,Nowotny P,Lotrich FE,Dore PM,Pollock BG, et al. 2013. Escitalopram reduces attentional performance in anxious older adults with high-expressing genetic variants at serotonin 2A and 1B receptors. Int J Neuropsychopharmacol 16:279–288.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, 2010. Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis. Curr Osteoporos Rep 8:15–22.
   PubMedGoogle Scholar
• Looker AC, Borrund LG, Dawson-Hughes B, Shepherd JA, Wright NC. 2012. Osteoporosis or low bone mineral mass at the femur neck or lumbar spine in older adults: United States, 2005–2008, In NCHS Data Brief No. 93. Hyattsville, MD: NCHS.
   Google Scholar
• Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry: J Mental Sci 134:382–389.
   PubMed Web of Science ®Google Scholar
• Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, et al; Committee on the Guidelines for the use of Biochemical Markers of Bone Turnover in Osteoporosis, J.O.S. 2005. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Mineral Metab 23:97–104.
   PubMed Web of Science ®Google Scholar
• O’Donnell JM, Shelton RC. 2011. Drug therapy of depression and anxiety disorders. In: Brunton LL, Knollmann BC, editors. Goodman & Gillman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill.
   Google Scholar
• Olfson M, Marcus SC. 2009. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 66:848–856.
   PubMed Web of Science ®Google Scholar
• Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, Goltzman D. 2007. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167:188–194.
   PubMed Web of Science ®Google Scholar
• Shea MLO, Garfield LD, Teitelbaum S, Civitelli R, Mulsant BH, Reynolds CF, et al. 2013. Serotonin-norepinepherine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resporption. Osteoporos Int 24: 1741–1749.
   PubMed Web of Science ®Google Scholar
• Steiger H, Richardson J, Joober R, Gauvin L, Israel M, Bruce KR, et al. 2007. The 5HTTLPR polymorphism, prior maltreatment and dramatic-erratic personality manifestations in women with bulimic syndromes. J Psychiatry Neurosci 32:354–362.
   PubMed Web of Science ®Google Scholar
• Thakur GA, Grizenko N, Sengupta SM, Schmitz N, Joober R. 2010. The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methyl phenidate in children with ADHD. BMC Psychiatry 10:50.
   PubMed Web of Science ®Google Scholar
• Wankerl M, Zyriax BC, Bondy B, Hinkelmann K, Windler E, Otte C. 2010. Serotonin transporter gene-linked polymorphic region (5-HTTLPR) and diurnal cortisol: A sex by genotype interaction. Biol Psychol 85:344–346.
   PubMed Web of Science ®Google Scholar
• Warden SJ, Nelson IR, Fuchs RK, Bliziotes MM, Turner CH. 2008. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause 15:1176–1183.
   PubMed Web of Science ®Google Scholar
• Warden SJ, Hassett SM, Bond JL, Rydberg J, Grogg JD, Hilles EL, et al. 2010a. Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels. Bone 46:985–992.
   PubMed Web of Science ®Google Scholar
• Warden SJ, Robling AG, Haney EM, Turner CH, Bliziotes MM. 2010b. The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 46:4–12.
   PubMed Web of Science ®Google Scholar
• Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL. 2006. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 11:224–226.
   PubMed Web of Science ®Google Scholar
• Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ. 2001. Expression of serotonin receptors in bone. J Biol Chem 276:28961–28968.
   PubMed Web of Science ®Google Scholar
• Westbroek I, Waarsing JH, van Leeuwen JP, Waldum H, Reseland JE, Weinans H, et al. 2007. Long-term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats. J Cell Biochem 101:360–368.
   PubMed Web of Science ®Google Scholar
• Yadav VK, Ducy P. 2010. Lrp5 and bone formation: a serotonin-dependent pathway. Ann NY Acad Sci 1192:103–109.
   PubMed Web of Science ®Google Scholar
• Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, et al. 2008. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825–837.
   PubMed Web of Science ®Google Scholar